These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34956909)

  • 1. A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports.
    Wang BR; Wan CL; Liu SB; Qiu QC; Wu TM; Wang J; Li YY; Ge SS; Qiu Y; Shen XD; Xue SL; Li Z
    Front Oncol; 2021; 11():797941. PubMed ID: 34956909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
    Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
    Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
    Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
    Li Z; Wang J; Ge SS; Qiu QC; Du JH; Shan SS; Shen XD; Wan CL; Wang BR; Wu DP; Qiu HY; Xue SL
    Front Oncol; 2022; 12():841276. PubMed ID: 35211416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
    Gu S; Hou Y; Dovat K; Dovat S; Song C; Ge Z
    Exp Hematol Oncol; 2023 Feb; 12(1):23. PubMed ID: 36849955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells.
    Urwanisch L; Unger MS; Sieberer H; Dang HH; Neuper T; Regl C; Vetter J; Schaller S; Winkler SM; Kerschbamer E; Weichenberger CX; Krenn PW; Luciano M; Pleyer L; Greil R; Huber CG; Aberger F; Horejs-Hoeck J
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
    Báez-Gutiérrez N; Rodríguez-Ramallo H; Moreno MA; Arboli ER; Abdel-Kader Martín L
    Ther Adv Hematol; 2021; 12():20406207211040335. PubMed ID: 34471510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
    Asai-Nishishita A; Kawahara M; Tatsumi G; Iwasa M; Fujishiro A; Nishimura R; Minamiguchi H; Kito K; Murata M; Andoh A
    Sci Rep; 2023 Sep; 13(1):14454. PubMed ID: 37660196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Watts J; Lin TL; Mims A; Patel P; Lee C; Shahidzadeh A; Shami P; Cull E; Cogle CR; Wang E; Uckun FM
    Front Oncol; 2021; 11():806243. PubMed ID: 35096610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
    Mao J; Li S; Zhao H; Zhu Y; Hong M; Zhu H; Qian S; Li J
    Am J Transl Res; 2018; 10(8):2567-2578. PubMed ID: 30210693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
    Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
    Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Yin Z; Gao Y; Bu X; Wang J; Yao Z; Liu Q; Zhang Y; Yu G; Ping B
    Leuk Lymphoma; 2024 Dec; 65(14):2138-2150. PubMed ID: 39235111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.